BridgeMD
New treatment option for Lower Respiratory Tract Infection
Official title The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
ClinicalTrials.gov ID: NCT05762302
What this study is testing
- What it's testing
- This is a Prospective, multi-center study enrolling adults subjects presented to the ED/Urgent care, with symptoms consistent with lower respiratory infection (LRTI). The reason of this study is to demonstrate the MeMed BV can help clinicians make decisions about using antibiotics in patients with lower respiratory track infections and see how it would impact clinical outcomes, antibiotics use, hospitalizations, ED clinicians find ways to improve health and medical care.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Patients eligible for inclusion are required to fulfill all of the following criteria:
- Written informed consent must be obtained from the patient or his/her legal guardian.
- 18 years of age or older.
- Current disease duration ≤ 7 days.
- Tactile fever or measured temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported), either of them noted at...
You likely can't join if
- Patients fulfilling any of the following criteria are not eligible for inclusion in the infectious cohort:
- Systemic antibiotics within 72 hours prior to enrollment
- Inflammatory disease (e.g., IBD, SLE, Rheumatoid arthritis, Kawasaki, other vasculitis)
- Congenital immune deficiency (CID)
- A proven or suspected infection on presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus)...
- HIV, HBV, or HCV infection (self-declared or known from medical records)
See the full eligibility criteria
- Patients eligible for inclusion are required to fulfill all of the following criteria:
- Written informed consent must be obtained from the patient or his/her legal guardian.
- 18 years of age or older.
- Current disease duration ≤ 7 days.
- Tactile fever or measured temperature ≥ 37.8°C (100°F) (any body site, any measurement device, including self-reported), either of them noted at least once within the last 7 days.
- Clinical suspicion of bacterial or viral LRTI: At least one of the following respiratory signs or symptoms: cough (new or worsening), sputum production, dyspnea/shortness of breath, auscultatory abnormality (e.g...
- Clinician intent to prescribe antibiotics based on the currently available data.
- Patients fulfilling any of the following criteria are not eligible for inclusion in the infectious cohort:
- Systemic antibiotics within 72 hours prior to enrollment
- Inflammatory disease (e.g., IBD, SLE, Rheumatoid arthritis, Kawasaki, other vasculitis)
- Congenital immune deficiency (CID)
- A proven or suspected infection on presentation with Mycobacterial (e.g., MAC, MABC), parasitic or fungal (e.g., Candida, Histoplasma, Aspergillus) pathogen
- HIV, HBV, or HCV infection (self-declared or known from medical records)
- Major surgery, trauma and\\or burns in the last 7 days
- Pregnancy- self reported or medically confirmed
- Active malignancy - Cancer diagnosed within the previous six months, recurrent, regionally advanced or metastatic cancer, cancer for which treatment had been administered within six months, or hematological cancer that...
- Patients with severe illnesses that affect life expectancy and quality of life such as end stage renal disease, end stage liver disease or severe COPD.
- Clinician intent to hospitalize patient.
- Patients with suspected concomitant infections (e.g. UTI, cellulitis, gastroenteritis, etc.)
- Active treatment with immune-suppressive or immune-modulating therapies, including without limitations: Administration of PO\\IV\\IM high dose steroids \>1mg/kg/day prednisone (or equivalent) at some point in the past...
The study team makes the final eligibility decision.
Where it's taking place
- Jacksonville, Florida, United States
- Kansas City, Kansas, United States
- Brooklyn, New York, United States
- Stony Brook, New York, United States
- Philadelphia, Pennsylvania, United States
- Charleston, South Carolina, United States
- Dallas, Texas, United States
- Milwaukee, Wisconsin, United States
- Haifa, North, Israel
- Haifa, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jacksonville, Florida, United States; Kansas City, Kansas, United States; Brooklyn, New York, United States; Stony Brook, New York, United States; Philadelphia, Pennsylvania, United States; Charleston, South Carolina, United States and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.